ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
60,335.54
-5.49%
S&P 500
5,065.28
-0.99%
Dow Jones
37,954.29
-1.12%
US Dollar vs Yen
157.7015
0.88%
Brent Oil
86.075
-1.39%
Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Alterity Therapeutics Limited (ATHE)

  7. Alterity Therapeutics Limited (ATHE) ニュース

ATHE Alterity Therapeutics Limited

2.12
-0.075 (-3.42%)
最終更新日： 03:16:23
15分遅延
名称 銘柄コード 市場 種別
Alterity Therapeutics Limited ATHE NASDAQ Depository Receipt
  前日比 前日比 % 現在値 時刻
Upgrade Icon
-0.075 -3.42% 2.12 03:16:23
始値 安値 高値 終値 前日終値
2.20 2.0202 2.20 2.195
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/4/3020:25GLOBEAppendix 4C – Q3 FY24 Quarterly Cash Flow Report
2024/4/2920:25GLOBEAlterity Therapeutics Presents New Data Demonstrating..
2024/4/1720:25GLOBEAlterity Therapeutics Parkinson’s Disease and Multiple..
2024/4/1020:25GLOBEAlterity Therapeutics to Present New Data on ATH434 at the..
2024/3/2623:25GLOBEAlterity Therapeutics Receives a A$3.9 Million Research &..
2024/2/2100:25GLOBEAlterity Therapeutics to Present New Data at the Upcoming..
2024/2/1607:29EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/2/1607:28EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
2024/2/0621:25GLOBEAlterity Therapeutics Phase 2 Data Monitoring Committee..
2024/1/3122:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/1/2921:24GLOBEAlterity Therapeutics to Participate in the ShareCafe Hidden..
2024/1/2221:25GLOBEAlterity Therapeutics Issues Shareholder Letter Highlighting..
2024/1/2220:12EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/1/1822:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/1/1207:19EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/1/1207:16EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/1/1020:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/1/0822:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/1/0822:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/1/0822:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/1/0822:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/1/0520:27EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/1/0520:24EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/1/0222:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/1/0222:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/1/0222:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/12/2922:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/12/2922:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/12/2122:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/12/2122:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/12/2114:30GLOBEAlterity Therapeutics Appoints Phillip Hains as Chief..
2023/12/0506:35GLOBEAlterity Therapeutics to Host Webcast to Discuss ATH434..
2023/12/0421:25GLOBEAlterity Therapeutics Reports Positive Efficacy Data for..
2023/11/2721:25GLOBEAlterity Therapeutics Announces Presentation of Novel..
2023/11/1621:25GLOBEAlterity Therapeutics Announces Presentation of New Data..
2023/11/0821:25GLOBEAlterity Therapeutics Completes Enrolment in ATH434-201..
2023/10/3020:25GLOBEAppendix 4C – Q1 FY24 Quarterly Cash Flow Report
2023/10/2613:15EDGAR2Form EFFECT - Notice of Effectiveness
2023/9/1319:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/8/3120:25GLOBEAlterity Therapeutics Presents New Data on Multiple System..
2023/8/2320:25GLOBEAlterity Therapeutics Granted New Composition of Matter..
2023/8/2220:25GLOBEAlterity Therapeutics Rare Disease Natural History Study to..
2023/8/1520:25GLOBEAlterity Therapeutics Receives a $4.74 million Research &..
2023/7/3120:52GLOBEAppendix 4C – Q4 FY23 Quarterly Cash Flow Report
2023/7/2620:25GLOBEAlterity Therapeutics Phase 2 Data Monitoring Committee..
2023/6/2120:25GLOBEAlterity Therapeutics to Present in MST Access Rare..
2023/5/3020:25GLOBEAlterity Therapeutics Initiates Second Phase 2 Study in Rare..
2023/5/1920:25GLOBEAlterity Therapeutics CEO David Stamler to Present at the..
2023/5/1020:25GLOBEAppendix 4C – Q3 FY23 Quarterly Cash Flow Report

最近閲覧した銘柄

NASDAQ
ATHE
Alterity Therapeutics
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有